5.1 Dental Pharmacology, Local Anesthetics, and Analgesics

2.1 Dental Pharmacology, Local Anesthetics, and Analgesics

INBDE Core Concept: Local anesthetics prevent pain perception by reversibly blocking voltage-gated sodium channels from the intracellular side of the nerve membrane. Successful clinical administration requires a firm grasp of chemical structure, pKa-driven onset dynamics, tissue pH alterations, vasoconstrictor dosage limits, and precise calculation of maximum recommended doses (MRD).

---

Mechanism of Action & Sodium Channel Blockade

Local anesthetic (LA) molecules consist of three distinct structural components:

1. Lipophilic aromatic ring: Facilitates penetration through the lipid nerve sheath and cell membrane.
2. Intermediate chain: Determines chemical classification as an amide (ester linkage absent) or an ester (ester linkage present).
3. Hydrophilic secondary or tertiary amine: Acts as a proton acceptor, rendering the molecule soluble in aqueous solutions.

Lipophilic Aromatic Group ── Intermediate Chain (Amide or Ester) ── Hydrophilic Amine

Intracellular Receptor Binding

Local anesthetics exist in solution in a dynamic equilibrium between two forms: the un-charged, un-ionized free base ($RN$) and the charged, ionized cation ($RNH^+$).

$\text{RNH}^+ \rightleftharpoons \text{RN} + \text{H}^+$

• Un-ionized Free Base ($RN$): Lipid-soluble form capable of diffusing across the hydrophobic nerve sheath (epineurium) and neuronal cell membrane.
• Ionized Cation ($RNH^+$): Water-soluble form that enters the open sodium channel pore from the intracellular side and binds to specific amino acid residues within the inner vestibule of the voltage-gated $\text{Na}^+$ channel.

By binding intracellularly, $RNH^+$ physically blocks the influx of sodium ions ($\text{Na}^+$), preventing nerve membrane depolarization. As a result, the threshold potential is not reached, action potentials are not generated, and nociceptive impulses fail to propagate along the axon.

---

Chemical Structure: Amides vs. Esters

Understanding the distinction between amide and ester LAs is critical for predicting metabolism, elimination, and potential hypersensitivity reactions.

Memory Aid: Amide local anesthetics contain two "i"s in their generic name (Lidocaine, Mepivacaine, Articaine, Bupivacaine, Prilocaine). Ester LAs contain only one "i" (Procaine, Tetracaine, Benzocaine).

The Articaine Exception

Articaine is chemically unique: it contains a thiophene ring (which enhances lipid solubility) and an ester side chain in addition to its amide linkage. Because of this ester group, 90% of articaine is rapidly hydrolyzed in the blood by plasma pseudocholinesterase, leaving only 10% for hepatic metabolism. This rapid plasma clearance results in a significantly shorter elimination half-life (~27 minutes vs. ~90 minutes for lidocaine) and a lower systemic toxicity profile.

---

Pharmacokinetics: pKa, Tissue pH, and Onset of Action

The dissociation constant ($pK_a$) of a local anesthetic represents the pH at which 50% of the drug exists in the un-ionized base form ($RN$) and 50% in the ionized cationic form ($RNH^+$).

• Lower $pK_a$ (closer to physiological pH 7.4): A higher percentage of un-ionized free base ($RN$) is available at physiological pH to penetrate the nerve membrane $\rightarrow$ Faster onset of anesthesia.
• Higher $pK_a$: A smaller fraction of $RN$ is available at pH 7.4 $\rightarrow$ Slower onset of anesthesia.

Clinical Impact of Tissue Acidosis (Infection)

In inflamed or infected tissue, local anaerobic metabolism lowers extracellular pH from 7.4 to 5.5–6.0. Applying the Henderson-Hasselbalch equation demonstrates that this acidic environment shifts the equilibrium heavily toward the ionized form ($RNH^+$):

$\text{pH} - pK_a = \log\left(\frac{[RN]}{[RNH^+]}\right)$

At pH 5.5, less than 1% of lidocaine exists as $RN$. Consequently, inadequate free base is available to cross the nerve membrane, explaining why local anesthetic injections frequently fail to produce adequate anesthesia in the presence of active tissue infection or abscesses.

---

Vasoconstrictors and Cardiac Dosage Limits

Vasoconstrictors (epinephrine, levonordefrin) are added to local anesthetics to counteract the intrinsic vasodilatory properties of LAs. Benefits include:

1. Decreased systemic absorption rate $\rightarrow$ reduced systemic toxicity.
2. Increased depth and duration of anesthesia.
3. Localized hemostasis at the surgical site.

Epinephrine Pharmacology

Epinephrine acts on both $\alpha_1$ receptors (causing localized vasoconstriction) and $\beta_1/\beta_2$ receptors (increasing heart rate, cardiac contractility, and bronchodilation).

• Standard Dental Cartridge Volume: 1.8 mL (or 1.7 mL for articaine in some jurisdictions; calculations standardly use 1.8 mL).
• Concentration Calculations:
  • 1:100,000 epinephrine = $0.01\text{ mg/mL} \times 1.8\text{ mL} = \mathbf{0.018\text{ mg epinephrine per cartridge}}$.
  • 1:200,000 epinephrine = $0.005\text{ mg/mL} \times 1.8\text{ mL} = \mathbf{0.009\text{ mg epinephrine per cartridge}}$.
  • 1:50,000 epinephrine = $0.02\text{ mg/mL} \times 1.8\text{ mL} = \mathbf{0.036\text{ mg epinephrine per cartridge}}$.

Maximum Recommended Epinephrine Doses

\text{Healthy Adult (Normal Max):} & \quad \mathbf{0.2\text{ mg epi per appointment}} \quad (\approx 11 \text{ cartridges of } 1:100,000) \\ \text{Cardiac Risk / Medically Compromised:} & \quad \mathbf{0.04\text{ mg epi per appointment}} \quad (\approx 2.2 \text{ cartridges of } 1:100,000) \end{aligned}$$ > **Clinical Scenario:** A 62-year-old male with a history of myocardial infarction 8 months ago requires operative dentistry. To remain under the cardiac maximum epinephrine dose of 0.04 mg, the dentist can administer a maximum of **2 full cartridges** of 2% lidocaine with 1:100,000 epinephrine. --- ## Maximum Recommended Doses (MRD) Table & Calculations Dosage limits must be calculated based on patient weight and absolute maximum caps. On the INBDE, dosages are routinely tested in milligrams per kilogram (mg/kg) or milligrams per pound (mg/lb). | Local Anesthetic | Concentration | mg per Cartridge | Manufacturer MRD (mg/kg) | Absolute Maximum Cap | | :--- | :---: | :---: | :---: | :---: | | **Lidocaine 2% + 1:100k Epi** | 20 mg/mL | **36 mg** | **7.0 mg/kg** (3.2 mg/lb) | **500 mg** | | **Articaine 4% + 1:100k Epi** | 40 mg/mL | **68 mg** (articaine cartridges hold **1.7 mL**, not 1.8 mL) | **7.0 mg/kg** (3.2 mg/lb) | **500 mg** | | **Mepivacaine 3% Plain** | 30 mg/mL | **54 mg** | **6.6 mg/kg** (3.0 mg/lb) | **400 mg** | | **Bupivacaine 0.5% + 1:200k Epi** | 5 mg/mL | **9 mg** | **1.3 mg/kg** (0.6 mg/lb) | **90 mg** | | **Prilocaine 4% Plain / 1:200k Epi** | 40 mg/mL | **72 mg** | **8.0 mg/kg** (3.6 mg/lb) | **600 mg** | ### Sample Dosage Calculation Problem *Patient:* 20 kg pediatric patient requiring restorative treatment. *Drug:* 2% Lidocaine with 1:100,000 epinephrine. 1. **Calculate Maximum Weight-Based Allowance:** $20\text{ kg} \times 7.0\text{ mg/kg} = \mathbf{140\text{ mg lidocaine}}$. 2. **Determine mg per Cartridge:** $2\% = 20\text{ mg/mL} \times 1.8\text{ mL} = \mathbf{36\text{ mg/cartridge}}$. 3. **Calculate Maximum Cartridges:** $140\text{ mg} / 36\text{ mg/cartridge} = \mathbf{3.88\text{ cartridges}}$ (round down to **3.5 cartridges** safely). > **Toxicity Warning:** **Prilocaine** and **Benzocaine** (topical) metabolize into *o-toluidine*, which oxidizes hemoglobin to methemoglobin. **Methemoglobinemia** manifests as cyanosis, slate-grey cutaneous discoloration, and hypoxia unresponsive to $O_2$. Antidote: Intravenous **methylene blue** (1–2 mg/kg). --- ## Dental Analgesics & Prescribing Guidelines Management of acute perioperative dental pain relies on non-opioid anti-inflammatory drugs as first-line therapy, reserving opioids for severe breakthrough pain. ### Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - **Mechanism:** Inhibit cyclooxygenase enzymes (**COX-1** and **COX-2**), blocking the conversion of arachidonic acid to pro-inflammatory prostaglandins. - **First-Line Regimen:** **Ibuprofen 400–600 mg** PO every 4 to 6 hours (ceiling analgesic effect achieved at 400 mg for mild-moderate pain). - **Adverse Effects:** Gastric mucosal ulceration (COX-1 inhibition), reversible platelet inhibition, nephrotoxicity, and blunting of antihypertensive medications. ### Acetaminophen (APAP) - **Mechanism:** Acts predominantly in the central nervous system to inhibit prostaglandin synthesis; possesses analgesic and antipyretic properties but **lacks peripheral anti-inflammatory or antiplatelet activity**. - **Maximum Daily Dose:** **3,000 mg/day** (standard healthy adult ceiling; 2,000 mg/day in chronic alcoholics or patients with hepatic impairment). - **Toxicity:** Overdose saturates glucuronide and sulfate conjugation pathways, converting APAP via CYP2E1 into N-acetyl-p-benzoquinone imine (**NAPQI**), a reactive metabolite causing hepatic necrosis. Antidote: **N-acetylcysteine (NAC)**, which replenishes hepatic glutathione stores. ### Synergistic Multimodal Analgesia Combining an NSAID with acetaminophen produces **superior analgesia compared to opioid monotherapy** without opioid-related side effects. $$\text{Synergistic Post-Op Pain Protocol:} \quad \text{Ibuprofen 400–600 mg} + \text{Acetaminophen 500–1000 mg Q6H}$$ ### Opioid Analgesics - **Mechanism:** $\mu$-opioid receptor agonists in the central nervous system (e.g., Codeine, Hydrocodone, Oxycodone, Tramadol). - **Prescribing Guidelines:** Limit initial prescriptions to a **3-day supply** for acute dental pain. Common adverse effects include nausea, sedation, constipation, and respiratory depression.